| 111.46 |  +0.45 / +0.41%Today’s Change | 103.66 Today|||52-Week Range 132.13 | -3.68% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $106.7B |
Company Description
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through the following segments: Human Pharmaceutical Products and Animal Health Products. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health Products segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
Employees
Shareholders
| Mutual fund holders | 38.79% |
| Other institutional | 28.17% |
| Individual stakeholders | 12.72% |
Top Executives
| David A. Ricks | Chairman, President & Chief Executive Officer |
| Myles Oneill | Senior VP & President-Manufacturing Operations |
| Joshua L. Smiley | Chief Financial Officer & Senior Vice President |
| Aarti S. Shah | Chief Information Officer & SVP-IT |
| Timothy J. Garnett | Chief Medical Officer & VP-Global Medical |
+0.45 / +0.41%
